Related Experiment Video
Updated: Jan 21, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Grazia R Tundo1, Diego Sbardella2, Pedro M Lacal3
1Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy, grazia.tundo@libero.it.
Background:
Immune checkpoints are critical regulatory pathways of the immune system which finely tune the response to biological threats. Among them, the CD-28/CTLA-4 and PD-1/PD-L1 axes play a key role in tumour immune escape and are well-established targets of cancer immunotherapy.
Summary:
The clinical experience accumulated to date provides unequivocal evidence that anti-CTLA-4, PD-1, or PD-L1 monoclonal antibodies, used as monotherapy or in combination regimes, are effective in a variety of advanced/metastatic types of cancer, with improved clinical outcomes compared to conventional chemotherapy. However, the therapeutic success is currently restricted to a limited subset of patients and reliable predictive biomarkers are still lacking. Key Message: The identification and characterization of additional co-inhibitory pathways as novel pharmacological targets to improve the clinical response in refractory patients has led to the development of different immune checkpoint inhibitors, the activities of which are currently under investigation. In this review, we discuss recent literature data concerning the mechanisms of action of next-generation monoclonal antibodies targeting LAG-3, TIM-3, and TIGIT co-inhibitory molecules that are being explored in clinical trials, as single agents or in combination with other immune-stimulating agents.
Insights
Next-generation immune checkpoint inhibitors targeting LAG-3, TIM-3, and TIGIT show promise for improving cancer immunotherapy responses in patients refractory to current treatments. Further clinical trials are investigating their efficacy as single agents or in combination therapies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoints, including CD-28/CTLA-4 and PD-1/PD-L1 axes, regulate immune responses and are crucial in tumor immune evasion.
- These axes are established targets for cancer immunotherapy, demonstrating effectiveness in various advanced cancers.
Purpose of the Study:
- To review recent literature on next-generation immune checkpoint inhibitors.
- To discuss the mechanisms of action of novel monoclonal antibodies targeting LAG-3, TIM-3, and TIGIT.
- To explore their potential in improving clinical response in patients resistant to current therapies.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of mechanisms of action for novel immune checkpoint inhibitors.
- Evaluation of combination strategies involving immune-stimulating agents.
Main Results:
- Current anti-CTLA-4, PD-1, and PD-L1 therapies improve outcomes in advanced cancers but benefit only a subset of patients.
- Reliable predictive biomarkers for these therapies are still needed.
- Next-generation inhibitors targeting LAG-3, TIM-3, and TIGIT are under investigation.
Conclusions:
- Novel immune checkpoint inhibitors targeting LAG-3, TIM-3, and TIGIT represent a promising avenue for enhancing cancer immunotherapy.
- These agents are being explored in clinical trials as monotherapy or in combination regimens.
- Further research is critical to overcome therapeutic resistance and expand patient benefits.
Related Concept Videos
02:56Treatment Resistant Cancers
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:21Schwarzschild Radius and Event Horizon
The minimum speed required to launch a projectile from the surface of an object to which it is gravitationally bound so that it eventually escapes the object’s gravitational field is called the escape velocity. The escape velocity is independent of the mass of the object. Merging the idea of escape...
01:38What is the Immune System?
01:36Humoral Immune Responses